Association between locomotive syndrome and the Japanese version of the EQ-5D-5L in middle-aged and elderly people in Japan

1) Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167.

2) Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of

patient assessed health outcome measures. BMJ. 2002;324(7351):1417.

13

Locomotive syndrome and Japanese version of the EQ-5D-5L

3) Aaronson N, Alonso J, Burnam A, et al. Assessing health status and quality-of-life instruments: attributes

and review criteria. Qual Life Res. 2002;11(3):193–205.

4) Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published

cost-utility analyses. Value Health. 2006;9(4):213–218.

5) Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan.

Health Econ. 2002;11(4):341–353.

6) Ikeda S, Shiroiwa T, Igarashi I, et al. Developing a Japanese version of the EQ-5D-5L value set [in

Japanese]. J Natl Inst Public Health. 2015;64(1):47–55.

7) Seichi A, Hoshino Y, Doi T, Akai M, Tobimatsu Y, Iwaya T. Development of a screening tool for risk of

locomotive syndrome in the elderly: the 25-question Geriatric Locomotive Function Scale. J Orthop Sci.

2012;17(2):163–712.

8) Hirano K, Imagama S, Hasegawa Y, Ito Z, Muramoto A, Ishiguro N. The influence of locomotive syndrome

on health-related quality of life in a community-living population. Mod Rheumatol. 2013;23(5):939–944.

9) Iizuka Y, Iizuka H, Mieda T, Tajika T, Yamamoto A, Takagishi K. Association between “loco-check” and

EuroQol, a comprehensive instrument for assessing health-related quality of life: a study of the Japanese

general population. J Orthop Sci. 2014;19(5):786–791.

10) Tanaka S, Ando K, Kobayashi K, et al. A low phase angle measured with bioelectrical impedance analysis

is associated with osteoporosis and is a risk factor for osteoporosis in community-dwelling people: the

Yakumo study. Arch Osteoporos. 2018;13(1):39.

11) Tanaka S, Ando K, Kobayashi K, et al. The decrease in phase angle measured by bioelectrical impedance

analysis reflects the increased locomotive syndrome risk in community-dwelling people: the Yakumo study.

Mod Rheumatol. 2019;29(3):496–502. doi: 10.1080/14397595.2018.1469582.

12) Tanaka S, Ando K, Kobayashi K, et al. The decreasing phase angles of the entire body and trunk during

bioelectrical impedance analysis are related to locomotive syndrome. J Orthop Sci. 2019;24(4):720–724.

doi: 10.1016/j.jos.2018.12.016.

13) Tanaka S, Ando K, Kobayashi K, et al. Utility of the serum cystatin c level for diagnosis of osteoporosis

among middle-aged and elderly people. Biomed Res Int. 2019;2019:5046852.

14) Imagama S, Hasegawa Y, Matsuyama Y, et al. Influence of sagittal balance and physical ability associated

with exercise on quality of life in middle-aged and elderly people. Arch Osteoporos. 2011;6(1–2):13–20.

15) Tanaka S, Ando K, Kobayashi K, et al. Increasing postural sway in balance test is related to locomotive

syndrome risk: a cross-sectional study. J Orthop Sci. 2019;24(5):912–917. doi: 10.1016/j.jos.2019.01.011.

16) Imagama S, Hasegawa Y, Ando K, et al. Staged decrease of physical ability on the locomotive syndrome risk

test is related to neuropathic pain, nociceptive pain, shoulder complaints, and quality of life in middle-aged

and elderly people - the utility of the locomotive syndrome risk test. Mod Rheumatol. 2017;27(6):1051–1056.

17) Tanaka S, Ando K, Kobayashi K, et al. Serum cystatin C is associated with locomotive syndrome

risk and can be an early predictor in community-living people: the Yakumo study. Mod Rheumatol.

2018;28(6):1035–1040.

18) Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level verion

of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.

19) Shiroiwa T, Ikeda S, Noto S, et al. Comparison of value set based on DCE and/or TTO data: scoring for

EQ-5D-5L health states in Japan. Value Health. 2016;19(5):648–654.

20) Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive

at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17(4):445–453.

21) Muramoto A, Imagama S, Ito Z, Hirano K, Ishiguro N, Hasegawa Y. Physical performance tests are useful

for evaluating and monitoring the severity of locomotive syndrome. J Orthop Sci. 2012;17(6):782–788.

22) Hirano K, Imagama S, Hasegawa Y, Wakao N, Muramoto A, Ishiguro N. Impact of back muscle

strength and aging on locomotive syndrome in community living Japanese women. Nagoya J Med Sci.

2013;75(1–2):47–55.

23) Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35.

24) Tanaka S, Ando K, Kobayashi K, et al. Relationship between locomotive syndrome and body composition

among community-dwelling middle-age and elderly individuals in Japan: the Yakumo study. Mod Rheumatol.

2019;29(3):491–495. doi: 10.1080/14397595.2018.1465645.

25) Dhillon V, Hurst N, Hannan J, Nuki G. Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture. Osteoporos Int.

2005;16(5):483–489.

26) Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee.

Rheumatol. 1999;38(9):807–813.

14

Satoshi Tanaka et al

27) Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization and comparison of

health-related utility in people with diabetes with various single and multiple vascular complications. Diabet

Med. 2006;23(10):1100–1105.

...